Fig. 2: Prophylactic effects of arketamine on the expression of heme-related mRNA levels in the spleen after LPS injection. | Translational Psychiatry

Fig. 2: Prophylactic effects of arketamine on the expression of heme-related mRNA levels in the spleen after LPS injection.

From: A role of splenic heme biosynthesis pathway in the persistent prophylactic actions of arketamine in lipopolysaccharide-treated mice

Fig. 2

A Alas2 mRNA in the spleen (one-way ANOVA: F2,28 = 20.61, P < 0.0001). B Fech mRNA in the spleen (one-way ANOVA: F2,28 = 10.04, P = 0.0005). C Hmbs mRNA in the spleen (one-way ANOVA: F2,28 = 5.096, P = 0.013). D Cpox mRNA in the spleen (one-way ANOVA: F2,28 = 1.207, P = 0.314). The data represent mean ± S.E.M. (n = 10 or 11). *P < 0.05, ***P < 0.001. E Expression of ALAS2 in the spleen from controls and MDD patients (Mann–Whitney U-test: U = 60.50, P = 0.030). F Expression of FECH in the spleen from controls and MDD patients (Mann–Whitney U-test: U = 51, P = 0.030). G Expression of HMBS in the spleen from controls and MDD patients (Mann–Whitney U-test: U = 69.50, P = 0.0759). The data represent mean ± S.E.M. (control n = 15. MDD n = 14). *P < 0.05, **P < 0.01.

Back to article page